Skip to main content
CADL
NASDAQ Life Sciences

Candel Therapeutics Reports Highly Positive Extended Phase 3 Data for Prostate Cancer Drug CAN-2409, Plans Q4 2026 BLA Submission

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$8.983
Mkt Cap
$642.376M
52W Low
$4.35
52W High
$9.27
52W Position info
106% above low
Off High info
3.1% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

CADL has more than doubled off its 52-week low of $4.35 on elevated volume (2.0× avg).

Summary

Candel Therapeutics reported compelling extended Phase 3 data for its prostate cancer therapy, CAN-2409, demonstrating significant improvements in disease-free survival and reduced metastasis, with a BLA submission planned for Q4 2026.


Key Events · Product Development and Regulatory · CADL

  • Extended Phase 3 Data Confirms Efficacy

    Extended follow-up data from the Phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer showed a statistically significant 39% improvement in prostate cancer-specific disease-free survival (HR=0.61; p=0.0031) after a median follow-up of 58 months.

  • Significant Reduction in Metastasis

    In the intermediate-risk prostate cancer subgroup (85% of patients), treatment with CAN-2409 resulted in a statistically significant 90% reduction in time to metastasis (HR=0.1; 95% CI 0.01-0.85) and a lower metastasis rate.

  • Favorable Tolerability Profile

    CAN-2409 in combination with standard-of-care radiation was generally well tolerated, with most treatment-related adverse events being mild to moderate and no Grade ≥4 events reported.

  • BLA Submission Planned for Q4 2026

    The company plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CAN-2409 in the fourth quarter of 2026.


Analysis · CADL · Life Sciences

Candel Therapeutics announced highly positive extended follow-up data from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer. The data reinforces the drug's efficacy, showing a statistically significant 39% improvement in prostate cancer-specific disease-free survival and a remarkable 90% reduction in time to metastasis in the intermediate-risk subgroup. This strong clinical validation, coupled with a favorable tolerability profile and the company's plan to submit a Biologics License Application (BLA) in Q4 2026, significantly de-risks the drug's path to market and could establish a new standard of care. This news comes as the stock trades near its 52-week high, suggesting strong investor confidence in the drug's potential.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CADL was trading at $8.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $642.4M. The 52-week trading range was $4.35 to $9.27. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CADL - Latest Insights

CADL
Nov 13, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $5.04 info
Change: -$0.0703 (-1%) info
Market Cap: $395.368M info
CADL
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $5.04 info
Change: -$3.35 (-40%) info
Market Cap: $395.368M info
CADL
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $5.04 info
Change: -$3.35 (-40%) info
Market Cap: $395.368M info
CADL
Oct 01, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $5.04 info
Change: -$5.36 (-52%) info
Market Cap: $395.368M info
CADL
Sep 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.96
Real-time Price: $5.04 info
Change: -$5.92 (-54%) info
Market Cap: $395.368M info